文献速递血液净化与透析慢性肾脏病

血清磷酸盐与血液透析患者骨脆性骨折风险增加相关

Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

COSMOS研究为3年前瞻性多中心观察性队列,纳入6797例血液透析患者。中位随访24个月,252例(4%)发生骨脆性骨折(发生率28.5/1000患者年)。基线血清磷酸盐>6.1 mg/dL与骨脆性骨折风险升高独立相关(HR 1.53,95%CI 1.10-2.13;复发事件HR 1.44,95%CI 1.02-2.05;竞争风险subHR 1.42,95%CI 1.02-1.98),但作为连续变量时未证实。

要点

  • 血液透析患者基线血清磷酸盐>6.1 mg/dL与骨脆性骨折风险升高独立相关。
  • 血清钙与骨脆性骨折风险无关联;PTH>800 pg/mL的关联在竞争风险分析后消失。
  • 血清磷酸盐作为连续变量时未证实与骨脆性骨折的关联。

核心结论

  • 高磷血症与血液透析患者骨脆性骨折风险增加独立且一致相关,提示血清磷酸盐可能是骨骨折的新风险因素。

研究设计与样本

  • COSMOS为3年、多中心、开放队列、前瞻性观察性研究,纳入6797例血液透析患者(20个欧洲国家227个中心)。
  • 采用标准Cox比例风险回归和复发事件Cox比例风险回归评估关联,并进行竞争风险分析(全因死亡为竞争事件)。
  • 多变量模型完全调整模型包括24个变量。

主要发现

  • 中位随访24个月,252例(4%)患者发生至少一次骨脆性骨折,发生率为28.5/1000患者年。
  • 骨折组与非骨折组:男性比例43.7% vs 61.4%,平均年龄68.1 vs 63.8岁,血液透析龄55.9 vs 38.3个月。
  • 基线血清磷酸盐>6.1 mg/dL(参考值4.3-6.1 mg/dL)与骨脆性骨折风险升高显著相关:标准Cox模型HR 1.53(95%CI 1.10-2.13),复发事件模型HR 1.44(95%CI 1.02-2.05)。
  • 竞争风险分析后关联持续:subHR 1.42(95%CI 1.02-1.98);但血清磷酸盐作为连续变量时未证实该发现。
  • 基线血清钙在任何回归模型中均与骨脆性骨折风险无关联;基线血清PTH>800 pg/mL在两种回归模型中与风险升高显著相关,但竞争风险分析后关联消失。

关键数值与推荐

  • 血清磷酸盐参考值4.3-6.1 mg/dL,>6.1 mg/dL为暴露分组。
  • 骨脆性骨折发生率28.5/1000患者年。
  • 血清磷酸盐>6.1 mg/dL:HR 1.53(95%CI 1.10-2.13)和HR 1.44(95%CI 1.02-2.05),subHR 1.42(95%CI 1.02-1.98)。
  • 血清PTH>800 pg/mL与骨脆性骨折风险升高显著相关,但竞争风险分析后关联消失。

临床怎么用

  • 在血液透析患者中,基线血清磷酸盐>6.1 mg/dL与骨脆性骨折风险升高独立相关,提示血清磷酸盐可能是骨骨折的新风险因素。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bone fragility fractures are associated with high morbidity and mortality. This study analysed the association between the current biochemical parameters of chronic kidney disease-mineral and bone disorders (CKD-MBD) and bone fragility fractures in the COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) project. METHODS: COSMOS is a 3-year, multicentre, open cohort, prospective, observational study carried out in 6797 haemodialysis patients (227 centres from 20 European countries). The association of bone fragility fractures (outcome) with serum calcium, phosphate and parathyroid hormone (PTH) (exposure), was assessed using standard Cox proportional hazards regression and Cox proportional hazards regression for recurrent events. Additional analyses were performed considering all-cause mortality as a competitive event for bone fragility fracture occurrence. Multivariable models were used in all strategies, with the fully adjusted model including a total of 24 variables. RESULTS: During a median follow-up of 24 months, 252 (4%) patients experienced at least one bone fragility fracture (incident bone fragility fracture rate 28.5 per 1000 patient-years). In the fractured and non-fractured patients, the percentage of men was 43.7% and 61.4%, mean age 68.1 and 63.8 years and a haemodialysis vintage of 55.9 and 38.3 months, respectively. Baseline serum phosphate >6.1 mg/dL (reference value 4.3-6.1 mg/dL) was significantly associated with a higher bone fragility fracture risk in both regression models {hazard ratio (HR) 1.53 [95% confidence interval (CI) 1.10-2.13] and HR 1.44 (95% CI 1.02-2.05)}. The significant association persisted after competitive risk analysis [subHR 1.42 (95% CI 1.02-1.98)] but the finding was not confirmed when serum phosphate was considered as a continuous variable. Baseline serum calcium showed no association with bone fragility fracture risk in any regression model. Baseline serum PTH >800 pg/mL was significantly associated with a higher bone fragility fracture risk in both regression models, but the association disappeared after a competitive risk analysis. CONCLUSIONS: Hyperphosphatemia was independently and consistently associated with an increased bone fracture risk, suggesting serum phosphate could be a novel risk factor for bone fractures in haemodialysis patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Barrera-Baena P, Rodríguez-García M, Rodríguez-Rubio E, et al. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients. Nephrol Dial Transplant. 2024. PMID: 37660283. doi:10.1093/ndt/gfad190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。